Real-World CAR-T Therapy Faces Persistent Logistical Barriers in Large B-Cell Lymphoma Treatment
核心洞察
Nearly two-thirds of CAR-T patients with large B-cell lymphoma experienced logistical disruptions including shipping delays and care coordination issues, according to analysis of 187 patient charts by Spherix Global Insights (搜索).
A majority of CAR-T patients required bridging therapy between leukapheresis and infusion, with targeted therapy being the most commonly used approach to maintain disease control during treatment delays.
The study reveals substantial opportunities for non-CAR-T therapies within the LBCL treatment continuum as physicians manage patients through manufacturing processes and access-related challenges.
Despite growing adoption of CAR-T therapy in large B-cell lymphoma (LBCL), new real-world evidence reveals that operational and logistical barriers continue to significantly impact patient management, creating substantial opportunities for alternative therapies during the treatment process. The findings from Spherix Global Insights (搜索)' latest Patient Chart Dynamix study highlight persistent challenges that may limit the full therapeutic potential of these advanced cellular therapies.
Widespread Logistical Disruptions Persist
Analysis of 187 audited LBCL patient charts revealed that nearly two-thirds of CAR-T patients experienced logistical disruptions prior to treatment. These disruptions included shipping delays, care coordination issues, prolonged vein-to-vein time, limited manufacturing slot availability, and insurance or access delays before infusion. The data, which included 20 patients who had previously received CAR-T therapy, provides critical insight into how these therapies perform outside controlled clinical settings.
The study, which combined attitudinal insights from 101 U.S. hematologist/oncologists with detailed patient-level data, offers a comprehensive view of real-world treatment sequencing and operational barriers as advanced therapies continue reshaping the LBCL landscape.
Bridging Therapy Becomes Standard Practice
The research demonstrates the extent to which physicians rely on interim treatment strategies to stabilize patients during the CAR-T process. A majority of CAR-T patients received bridging therapy between leukapheresis and infusion, with targeted therapy representing the most commonly utilized approach, followed by chemotherapy and corticosteroids.
The primary goal of bridging therapy was disease control while awaiting CAR-T infusion, though physicians also cited symptom management and cytoreduction prior to infusion as key objectives. These findings point to a substantial and potentially expanding opportunity for non-CAR-T therapies to play a critical role within the broader LBCL treatment continuum.
Current CAR-T Product Utilization
Among patients who received CAR-T therapy, the majority underwent infusion between 2023 and 2026, reflecting the growing adoption of these therapies in recent years. Kymriah (Novartis) was the most commonly reported CAR-T product among audited patients, followed by Yescarta (Kite (搜索)) and Breyanzi (Bristol Myers Squibb (搜索)).
The research highlights the continued complexity of CAR-T utilization in real-world practice, where operational realities significantly influence treatment sequencing decisions. While manufacturers continue emphasizing improvements in turnaround time and treatment coordination, the study indicates that logistical disruptions remain widespread in routine practice.
Implications for Treatment Strategy
The findings reveal how operational realities are influencing treatment sequencing decisions in LBCL, capturing not only physician attitudes toward emerging therapies but also the specific patient characteristics, treatment pathways, and logistical hurdles shaping real-world management decisions across lines of therapy and practice settings.
These results suggest that as physicians work to manage patients through delays, manufacturing processes, and access-related challenges associated with cellular therapy, there remains a critical need for effective supportive treatment strategies and alternative therapeutic options to bridge the gap between treatment initiation and CAR-T infusion.